AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04048148 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Novel designed myopia control spectacle lenses
Description: A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.
Study NCT02115646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractionated carbon dioxide laser
Description: patients will have serial laser treatments
Study NCT01051232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active
Description: Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
Study NCT01051232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subjects will receive the placebo under fasting condition.
Study NCT01051232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active
Description: Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
Study NCT01051232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active
Description: Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: i.v., 375 mg/m2, d0 or d1 of each treatment cycle
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: i.v., 375 mg/m2, d0 or d1 of each treatment cycle
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: i.v., 750 mg/m2, d1 of each treatment cycle
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: i.v., 750 mg/m2, d1 of each treatment cycle
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: i.v., 50 mg/m2, d1 of each treatment cycle
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal Doxorubicin
Description: i.v., 50 mg/m2, d1 of each treatment cycle
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristin
Description: i.v., 2mg, d1 of each treatment cycle
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristin
Description: i.v., 2mg, d1 of each treatment cycle
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: p.o., 100mg, d1 - d5 of each treatment cycle
Study NCT00575406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: p.o., 100mg, d1 - d5 of each treatment cycle
Study NCT04071444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin program
Description: The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
Study NCT02524223 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Systematic HPV DNA assay in semen and cervicovaginal scrape
Description: Screening of HPV status at the genital level of males enrolled in MAP program.
Study NCT02524223 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Systematic HPV DNA cervicovaginal scrape
Description: Screening of HPV status at the genital level of females enrolled in MAP program.
Study NCT02524223 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: systematic HPV Status in newborns in case of pregnancy
Study NCT01390363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Only Phone Call
Description: A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
Study NCT01390363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent and Adolescent Phone Call
Description: A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
Study NCT02623088 — intervention group
Intervention type: OTHER
Intervention: PAP Therapies (CPAP)
Description: Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
Study NCT05680350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Exploration
Description: Laparoscopic Exploration to diagnose \& grade endometriosis
Study NCT05680350 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Estimation of Plasma Expression level of MICRO RNA 203 & 210
Description: estimation of Plasma Expression level for GeneMicro RNA 203 \& 210 by qRT-PCR
Study NCT02083315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130 1.5 mg
Description: TRV130 1.5 mg IV x 1 dose
Study NCT02083315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130 3 mg
Description: TRV130 3 mg IV x 1 dose
Study NCT02083315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130 4.5 mg
Description: TRV130 4.5 mg IV x 1 dose
Study NCT02083315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 10 mg
Description: Morphine 10 mg IV x 1 dose
Study NCT02083315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% in water IV x 1 dose
Study NCT01195714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
Study NCT04035642 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT 24 Gy Single dose
Description: Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.
Study NCT04035642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)
Description: Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
Study NCT04035642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal balloon with air filling
Description: A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
Study NCT04035642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urethral catheter loaded with beacon transponders
Description: A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
Study NCT03151018 — intervention group
Intervention type: DEVICE
Intervention: Resolute Onyx
Study NCT01652365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RDT Training and Subsidy Offered
Study NCT01652365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information/Education Campaign
Study NCT03432013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CUD-AMT
Description: Participants will be trained to manage their negative thoughts and emotions while also receiving treatment for cannabis misuse
Study NCT03432013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SUD-CBT
Description: Participants will receive traditional cognitive behavioral therapy for substance use disorder
Study NCT06348693 — intervention group
Intervention type: OTHER
Intervention: cell isolation from tumor biopsies and biomarker investigation
Description: cellular and molecular analysis on cancer stem cells and endothelial cells from tumor biopsies and investigation of tissue and systemic biomarkers
Study NCT01610466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic bariatric surgery ex-vivo training curriculum
Description: The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
Study NCT03976713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei Yishen granule
Description: Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
Study NCT03976713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bufei Yishen granule
Description: Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
Study NCT03976713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Powder for Inhalation
Description: Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
Study NCT03976713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium Bromide Powder for Inhalation
Description: Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
Study NCT01834963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa、Fluorouracil
Description: Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks
Study NCT01834963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin、Fluorouracil
Description: Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks
Study NCT02208726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose pillules
Description: Unmedicated sucrose pillules
Study NCT02208726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathic homaccord
Description: Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
Study NCT03190577 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample
Description: two 5 ML EDTA tubes of blood will be collected once by patient
Study NCT00758849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
Study NCT00758849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fipamezole
Description: One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
Study NCT00858910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) training
Description: MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
Study NCT00858910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control intervention
Description: The control intervention encloses relaxation and breathing exercises, and information about:~* the disease (stroke),~* therapy options,~* self-help groups and their offers for support,~* helping aids for independent living at home.
Study NCT03909659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary sodium reduction
Description: A supply of a reduced-sodium added-potassium salt substitute
Study NCT05063409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Blood product transfusion at a ratio of 1:1 FFP to PRBC or 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
Study NCT04188821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast drain removal
Description: Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing (complicated, see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care.
Study NCT04188821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: breast drain removal
Description: Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing (complicated, see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care.
Study NCT00376948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Study NCT00376948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT00376948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT01568164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PliCath HF System
Description: This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
Study NCT03604419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 100 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo
Study NCT03604419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB-119 100 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo
Study NCT03604419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 150 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo
Study NCT03604419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB-119 150 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo
Study NCT03604419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 200 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo
Study NCT03604419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB-119 200 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo
Study NCT03604419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 placebo + Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo
Study NCT04055402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessments
Description: The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.
Study NCT04055402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Completion of a baseline questionnaire and a 1-month follow-up survey.
Study NCT00405678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Subjects receiving chemo with exercise training
Study NCT00405678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chemo only
Description: Subjects receiving chemo only
Study NCT04494659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib capsule
Description: single dose and co-administrated with Rifampicin capsule
Study NCT04494659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin capsule
Description: repeated doses of Rifampicin capsule
Study NCT00771537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Sidedness
Description: There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.
Study NCT02240407 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase
Description: The dose selected for this study is a fixed dose of 4.6 x 10\^13 vg per TA muscle (range of 7.64 x 10\^11 vg/gm to 4.6 x 10\^11 vg/gm based on TA weight).
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rapamycin
Description: Patients will receive Rapamycin (dose 0.6-2 mg/m\^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until four months after second injection.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Patients will receive Rapamycin (dose 0.6-2 mg/m\^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until four months after second injection.
Study NCT02240407 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: saline
Description: Same volume as rAAV9-DES-hGAA injection will be used.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rituxan
Description: Patients will receive Rituxan (dose: 750 mg/m\^2 twice) 21 and 7 day prior first AAV9 injection, with a Rituxan dose 375 mg/m\^2 on the day of the injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 375 mg/m\^2.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: Patients will receive Rituxan (dose: 750 mg/m\^2 twice) 21 and 7 day prior first AAV9 injection, with a Rituxan dose 375 mg/m\^2 on the day of the injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 375 mg/m\^2.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Diphenhydramine
Description: 25-50mg will be provided before each Rituximab dose.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25-50mg will be provided before each Rituximab dose.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Acetaminophen
Description: We will provide 650 mg of tylenol before each dose of Rituximab.
Study NCT02240407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: We will provide 650 mg of tylenol before each dose of Rituximab.